payor coverage

The program, called Genetic Testing Solution, went into effect July 1 among Anthem Blue Cross' fully-insured and self-insured members.

Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.

Starting Oct. 1, the insurer will require clinicians and labs who order genetic and molecular tests for their patients to first get approval. 

The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.

The long-term pricing contract covers hereditary cancer testing, GeneSight, and a number of other diagnostics, but doesn't extend to coverage. 

The company said the number of lives now covered for EndoPredict has gone up to 109 million.

The company said it now has payor coverage for more than 130 million individuals.

The company obtained out-of-state provider status from California's Medicaid program for its OVA1 test, giving it access to more than 12 million patients. 

The firm said that the new coverage for its Afirma thyroid cancer test makes it a medically necessary benefit for nearly 24 million Blues plan members.